GTOnco™ I-O Assays for In Vivo Study
With years of experience in gene therapy-based I-O drugs discovery, Creative Biolabs has been developed various robust animal models and related in vivo assays to greatly facilitate I-O therapy development. Such as the established syngeneic mouse tumor models and humanized mouse models (HIS) allow our clients to study the host immune system. The profiling and monitoring of immune cell-mediated anti-tumor response are also available. To meet the needs of your specific I-O drugs development in gene therapy, we have the flexibility and expertise to develop custom assays for in vivo study. GTOnco™ platform is established to provide a comprehensive approach for in vivo efficacy studies and to underlie safety profile and action mechanisms of candidate I-O drugs, in the presence of a functionally immunocompetent system.
At GTOnco™, we provide a broad range of syngeneic tumor models as well as baseline tumor infiltrate flow data to inform model selection.
Profiling and Monitoring of Anti-tumor Immune Responses
Figure 1. Mechanisms of anti-tumor immunity stimulated by I-O drugs. (Twumasi, 2018)
Cytokines are important in gene therapy-based I-O drugs development, specifically in host responses to immune responses and cancer. GTOnco™ provides various cytokine detection by ELISA or ELISpot assays, such as chemokines, interferons, interleukins, lymphokines, and tumor necrosis factors.
Cell activation and proliferation are expected to be earlier indicators of the response to immune stimuli, and the related assays have been shown to be useful for monitoring T-cell immune status. At Creative Biolabs, GTOnco™ is able to provide faster, easier-to-use methods for measuring T-cell activation and proliferation in response to a variety of stimuli.
T cells persistence is likely to promote long-term anti-tumor effects in I-O drug therapy, such as adoptive T cell transfer. In addition, active T cells reprogram the trafficking properties of T cells and allow them to effectively and specifically settle to extra lymphoid organs. GTOnco™ platform has established effective in vivo methods to study the T cell persistence and provides the observations of organ-specific homing of T cells.
Creative Biolabs is capable of conducting many tests to evaluate the immune cell-mediated tumor regression efficacy in I-O drugs therapy, such as in vivo imaging and flow cytometry. By utilizing appropriate animal models, GTOnco™ platform provides the high-quality therapeutic efficacy test services to help our customers and expedite their IND application.
The dissociation kinetics of TCR binding to peptide-major histocompatibility molecules (pMHC) is a robust and stable biomarker of CD8+ T cell potency. The TCR-pMHC dissociation rates accurately predict the cytokine production, cell proliferation, and in vivo antitumor potency of naturally occurring antigen-specific CD8+ T cells.
Gene therapy-based I-O drugs that recruit and redirect T cells to attack tumor cells have tremendous potential for various malignancies treatment, such as the bi-specific T-cell engagers (BiTEs), a molecule with two antigen binding specificities to redirect immune effector cells to kill tumor cells.
Creative Biolabs is able to help you design the best assays for customized in vivo studies to support your gene therapy-based I-O drugs discovery. All our experiments are performed by well-trained technicians in a GLP-compliant and IACUC-regulated facility. Please feel free to contact us by E-mail for a quote and further discussion with our scientists.
Reference
- Twumasi-Boateng, K.; et al. (2018). Oncolytic viruses as engineering platforms for combination immunotherapy. Nature Reviews Cancer, 18(7), pp.419-432.
